Form 4: Regulus Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Crispina Balsada, CFO of Regulus Therapeutics, reports acquisition of stock options.
Summary
- Crispina Balsada, Chief Financial Officer of Regulus Therapeutics Inc. (RGLS), filed a Form 4 with the SEC.
- The filing reports the acquisition of stock options on May 20, 2024.
- Balsada acquired options to purchase 462,000 shares of common stock at an exercise price of $2.01.
- The options vest ratably on a monthly basis over 48 months, contingent upon continuous service to Regulus.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a company executive. It doesn't inherently indicate positive or negative company performance.
Positives
- The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by the CFO as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of earliest transaction (acquisition of stock options) |
| 05/19/2034 | Expiration date of the stock options |
| 05/21/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.